Document:

<PAGE>

                                  EXHIBIT 10(f)

         Schedule 10(f) identifying lock-up agreements that are substantially
         similar to Exhibit 10(e) in all material respects except as to the
         parties thereto and the amount of shares of common stock of the company
         that are locked up.

Total Shareholders  Locked up    Total Shares  Locked up
-----------------------------    -----------------------
       147                       283,650,000

                                       1<PAGE>

                                  EXHIBIT 10(i)

                              CONSULTING AGREEMENT

         This Consulting Agreement is made as of September 1, 2002 between Marc
Pharmaceuticals, Inc., a Delaware corporation (the "Company") and Dr. Brij B.
Saxena, Ph.D. (the "Consultant"), a principal investigator of the Weill Medical
College of Cornell University ("WMC") at WMC's laboratory at Cornell University
(the "University").

         A. The Company is engaged in scientific research in chemotherapy (the
"Field") to develop and exploit a site-directed chemotherapeutic agent to
selectively attack only cancer cells and by apoptosis destroy the DNA and
thereby cell proliferation (the "Technology").

         B. The Company has entered into a Sponsored Research Agreement (the
"Research Agreement") with WMC and Consultant dated June 19, 2002 relating to
the development of the Technology.

         C. The Company has also entered into an Exclusive License Agreement
(the License Agreement") with Cornell Research Foundation, Inc. dated June 19,
2002 relating to the licensing by the Company of certain patent rights relating
to the Technology.

         D. The Consultant has extensive experience in the Field, and the
Company seeks to benefit from the Consultant's expertise by retaining the
Consultant as a consultant. The Consultant wishes to perform consulting services
in the Field for the Company.

         Accordingly, the Company and the Consultant agree as follows:

1.       Services.

          (a)  The Consultant shall provide advice and consulting services to
               the Company with respect to matters related to the Field. The
               Consultant shall be engaged by the Company as a consultant only
               and shall not direct or conduct research for or on behalf of the
               Company, except on behalf of WMC pursuant to the Research
               Agreement. Consultant's services shall be those reasonably
               required by the Company from time to time, including, without
               limitation, assistance in preparation of materials and
               information for use in investment offering materials to be
               prepared by the Company, attendance at meetings with prospective
               and current investors, attendance at meetings with prospective
               and current business partners and general advice and consultation
               concerning the Technology and the Company's business and
               prospects. Consultant's services shall be performed at such
               locations as the Company shall from time to time designate. In no
               event shall the Consultant have direct conversations with any
               third parties concerning the Technology, the Company or its
               business, whether or not on behalf of the Company, unless
               specifically directed to do so by the Company and when
               accompanied by a representative of the Company.

                                       1
<PAGE>

          (b)  Upon request by the Company, and at times mutually agreed upon by
               the Company and the Consultant, the Consultant shall devote up to
               3 full days per month to provide consulting services to the
               Company pursuant to this Agreement.

          (c)  The Company acknowledges that the Consultant is an employee of
               WMC and is subject to WMC's policies, including policies
               concerning consulting, conflicts of interest, and intellectual
               property.

          (d)  Consultant shall perform his services under this Agreement to the
               best of his abilities and in accordance with the highest
               professional standards.

2.       Compensation.

          As full consideration for the consulting services provided by the
          Consultant, the Company shall pay to the Consultant the amount of
          $1,000 for each day that the Consultant shall perform consulting
          services for the Company, payable monthly, within 20 days after the
          end of each month during which Consultant shall perform consulting
          services for the Company. In addition to the foregoing amount, the
          Company shall promptly, upon invoice, reimburse the Consultant for all
          reasonable expenses incurred by the Consultant in providing consulting
          services under this Agreement.

3.       Competition

          (a) The Consultant represents to the Company that the Consultant does
          not have any agreements to provide consulting services to any other
          party, firm or company in the pharmaceutical industry on matters
          relating to the Field, except for the agreement(s) listed on Schedule
          A annexed to this Agreement with the parties therein named (the "Other
          Companies"). During the term of this Agreement, the Consultant shall
          not consult for any entity in the pharmaceutical industry other than
          the Company and the Other Companies on matters relating to the Field.

          (b) The Company acknowledges and agrees, however, that nothing in this
          Agreement shall affect the Consultant's obligations to, or research on
          behalf of, WMC or the University, including, without limitation,
          obligations or research of the Consultant in connection with transfer
          by WMC or the University of materials or intellectual property
          developed in whole or in part by the Consultant, or in connection with
          research collaborations.

4.       Confidentiality

          (a) The Consultant may disclose to the Company any information that
          the Consultant would normally freely disclose to other members of the
          scientific community at large, whether by publication, by presentation
          at seminars, or in informal scientific discussions. However, the
          Consultant

                                       2
<PAGE>

          shall not disclose to the Company information that is proprietary to
          WMC or the University and is not generally available to the public
          other than through formal technology transfer procedures or pursuant
          to the Research Agreement or the License Agreement.

          (b)  In providing consulting services to the Company pursuant to this
               Agreement, the Consultant may acquire information that pertains
               to the Company's business, products, processes, equipment,
               programs, developments, or plans and that is both (i) disclosed
               or made known by the Company to the Consultant and (ii)
               identified as "proprietary" by the Company at any time
               ("Proprietary Information"). The Consultant agrees not to
               disclose any Proprietary Information to third parties or to use
               any Proprietary Information for any purpose other than
               performance of consulting services pursuant to this Agreement,
               without the prior written consent of the Company.

          (c)  Proprietary Information subject to paragraph 4(b) does not
               include information that: (i) is or later becomes available to
               the public through no breach of this Agreement by the Consultant;
               (ii) is obtained by the Consultant from a third party who had the
               legal right to disclose the information to the Consultant; or
               (iii) is already in the possession of the Consultant on the date
               this Agreement becomes effective. In addition, Proprietary
               Information subject to paragraph 4(b) does not including
               information generated by the Consultant, alone or with others,
               unless the information (I) is generated solely as a direct result
               of the performance of consulting services under this Agreement
               and (II) is not generated in the course of the Consultant's
               activities as a WMC employee or University faculty member.

5.       Return of Materials

          The Consultant agrees to promptly return, following the termination of
          this Agreement or upon earlier request by the Company, all drawings,
          tracings, and written materials in the Consultant's possession and (i)
          supplied by the Company in conjunction with the Consultant's
          consulting services under this Agreement; or (ii) generated by the
          Consultant in the performance of Consultant under this Agreement and
          not generated in the course of the Consultant's activities as a WMC
          employee or University faculty member.

6.       Intellectual Property

          (a)  Subject to the terms of paragraph 6(b), below, the Consultant
               hereby assigns to the Company any right, title and interest he
               may have in any invention, discovery, improvement or other
               intellectual property which (i) the Consultant, alone or with
               others, develops solely as a direct result of performing
               consulting services for the Company under this Agreement and

                                       3
<PAGE>

               (ii) is not developed in the course of Consultant's activities as
               a WMC employee or University faculty member. (Any intellectual
               property assignable to the Company pursuant to the preceding
               sentence is hereinafter referred to as "Company Intellectual
               Property"). Upon the request of the Company, the Consultant shall
               execute such further assignments, documents and other instruments
               as may be necessary to assign Company Intellectual Property to
               the Company and to assist Company in applying for, obtaining and
               enforcing patents or other rights in the United States and in any
               foreign country with respect to any Company Intellectual
               Property. The Company will bear the cost of preparation of all
               patent or other applications and assignments, and the cost of
               obtaining and enforcing all patents and other rights to Company
               Intellectual Property.

          (b)  The Company shall have no rights by reason of this Agreement in
               any publication, invention, discovery, improvement or other
               intellectual property whatsoever, whether or not publishable,
               patentable or copyrightable, which is developed as a result of a
               program of research financed, in whole or in part, by funds
               provided by or under the control of WMC or the University. The
               Company also acknowledges and agrees that it will enjoy no
               priority or advantage as a result of the consultancy created by
               this Agreement in gaining access, whether by license or
               otherwise, to any proprietary information or intellectual
               property that arises from any research undertaken by the
               Consultant in his capacity as an employee of WMC or a member of
               the faculty of the University.

7.       Defense and Indemnification

               The Company agrees, at its sole expense, to defend WMC against,
               and to indemnify and hold WMC harmless from, any liability,
               claim, judgment, cost, expense, damage, deficiency, loss or
               obligation, of any kind or nature (including, without limitation,
               reasonable attorneys' fees and other costs and expenses of
               defense) relating to a claim or suit by a third party against
               WMC, either arising from this Agreement, the Consultant's
               performance of services for the Company under this Agreement, or
               any Company products or services which result from the
               Consultant's performance of services under this Agreement.

8.       Term and Termination

          (a)  Unless terminated earlier under paragraph 8(b), below, this
               Agreement shall be for a term of 36 months.

          (b)  Without limiting any rights which either party to this Agreement
               may have by reason of any default by the other party each party
               reserves the right to terminate this Agreement at its convenience
               by written notice given to the other party. Such termination
               shall be effective upon the date not earlier

                                       4
<PAGE>

               than 30 days following the date of such notice as shall be
               specified in said notice.

          (c)  Termination of this Agreement shall not affect (i) the Company's
               obligations to recognize the priority of WMC and University
               intellectual property rights under paragraph 6(b), above, (ii)
               the Company's obligations to defend and indemnify WMC under
               paragraph 7, above, (iii) the Company's obligation to pay for
               services previously performed by the Consultant or expenses
               reasonably incurred by the Consultant for which the Consultant is
               entitled to reimbursement under paragraph 2, above, or (iv) the
               Consultant's continuing obligations to the Company under
               paragraphs 4(b) and 6(a), above.

9.       Miscellaneous

          (a)  This Agreement shall inure to the benefit of and be binding upon
               the respective heirs, executors, successors, representatives, and
               assigns of the parties, as the case may be: provided, however,
               the obligations hereunder of each party to the other are personal
               and may not be assigned without the express written consent of
               such other party.

          (b)  The relationship created by this Agreement shall be that of
               independent contractor; and the Consultant shall have no
               authority to bind or act as agent for the Company or its
               employees for any purpose.

               Consultant acknowledges that he is an independent contractor and
               that this Agreement shall not give or extend to Consultant any
               rights with respect to additional compensation by Company nor to
               any deferred compensation plan, bonus plan or fringe benefits,
               and further agrees to hold Company harmless from any employment,
               income or other taxes which may be assessed in connection with
               payments to Consultant under this Agreement.

          (c)  The Company may use the Consultant's name, and in doing so may
               cite the Consultant's relationship with WMC, so long as any such
               usage (i) is limited to reporting factual events or occurrences
               only, and (ii) is made in a manner that could not reasonably
               constitute an endorsement of the Company or of any Company
               program, product or service. However, the Company shall not use
               the Consultant's name or WMC's name in any press release, or
               quote the Consultant in any company materials, or otherwise use
               the Consultant's name or WMC's name in a manner not specifically
               permitted by the preceding sentence or prohibited by either the
               Research Agreement or the License Agreement, unless in each case
               the Company obtains in advance the written consent of WMC and, in
               the case of the use of the Consultant's name, the Consultant's
               consent as well.

                                       5
<PAGE>

          (d)  Notice given by one party to the other hereunder shall be in
               writing and deemed to have been properly given or paid if
               deposited with the United States Postal Service, registered or
               certified mail, addressed as follows:

               To Consultant:   Dr. Brij B. Saxena, Ph.D.
                                Weill Medical College of Cornell University
                                1300 York Avenue
                                New York, New York 10021

               To Company:      Marc Pharmaceuticals, Inc.
                                One Canterbury Green, 8th Floor
                                Stamford,  Connecticut 06901
                                Attention:  Joel San Antonio

          (e)  This Agreement supersedes all previous agreements and discussions
               relating to the consulting services and constitutes the entire
               agreement between the Company and the Consultant with respect to
               the consulting services. This Agreement may not be modified in
               any respect by any verbal statement, representation, or agreement
               made by an employee, officer, or other representative of the
               Company and by the Consultant. The Company and the Consultant
               acknowledge and agree that any amendment of this Agreement
               (including, without limitation, any extension of this Agreement
               or any change from the terms of paragraph 2 in the consideration
               to be provided to the Consultant with respect to services to be
               provided hereunder, or any departure from the terms or conditions
               hereof with respect to he Consultant's consulting services for
               the Company) is subject to WMC's prior written approval.

          (f)  If any provision of this Agreement is adjudicated to be invalid,
               unenforceable, contrary to, or prohibited under applicable laws
               or regulations of any jurisdiction, such provision shall be
               severed and the remaining provisions shall continue in full force
               and effect.

          (g)  The Consultant and the Company acknowledge that (i) the
               Consultant is entering into this Agreement in his, individual
               capacity and not as an employee or agent of WMC, (ii) WMC is not
               a party to this Agreement and has no liability or obligation
               hereunder, and (iii) WMC is an intended third-party beneficiary
               of this Agreement and certain provisions of this Agreement are
               for the benefit of WMC and are enforceable by WMC in its own
               name.

          (h)  The parties hereto agree to perform any further acts and to
               execute and deliver any further documents which may be necessary
               or appropriate to carry out the purposes of this Agreement.

                                       6
<PAGE>

          (i)  If any provision of this Agreement is held to be unenforceable,
               invalid or illegal by any court of competent jurisdiction, such
               unenforceable, invalid, or illegal provision shall not affect the
               remainder of this Agreement.

          (j)  The validity of this Agreement and the interpretation and
               performance of all of its terms shall be governed by the
               substantive laws of the State of New York.

          (k)  Failure by either party hereto to insist upon strict compliance
               with any of the terms, covenants and condition hereof shall not
               be deemed a waiver or relinquishment of any similar right or
               power hereunder at any subsequent time or of any other provision
               hereof.

         IN WITNESS WHEREOF, the parties have executed this Agreement effective
the date first stated above.

                                     ------------------------------------
                                     Dr. Brij B. Saxena

                                     Marc Pharmaceuticals, Inc.

                                     By:
                                        ---------------------------------

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]